BioDrugs (2017) 31:357–367 DOI 10.1007/s40259-017-0232-7 OR IGINAL RESEARCH ARTIC L E Efﬁcacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial 1 2 3 4 • • • • Dae Hyun Yoo Chang-Hee Suh Seung Cheol Shim Slawomir Jeka 5 6 7 • • • Francisco Fidencio Cons Molina Pawel Hrycaj Piotr Wiland 8 9 10 • • • Eun Young Lee Francisco G. Medina-Rodriguez Pavel Shesternya 11 12 13 • • • Sebastiao Radominski Marina Stanislav Volodymyr Kovalenko 14 15 16 17 • • • • Dong Hyuk Sheen Leysan Myasoutova Mie Jin Lim Jung-Yoon Choe 18 18 18 16 • • • Sang Joon Lee Sung Young Lee Sung Hwan Kim Won Park Published online: 13 June 2017 The Author(s) 2017. This article is an open access publication Abstract or RTX 1000 mg at weeks 0 and 2. Based on disease Background CT-P10 is a biosimilar of innovator ritux- activity, patients could receive a second course of treat- imab (RTX), a biological therapy used to treat patients ment between weeks 24 and 48.
BioDrugs – Springer Journals
Published: Jun 13, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera